AstraZeneca Pharma India Limited
ASTRAZEN · General/Diversified · NSE
₹8,489
Current Market Price
Fair Value (DCF)
₹2,099
Margin of Safety
-75.3%
Updated just now
YieldIQ Score
58/100
Piotroski F-Score
7/9
Economic Moat
Moderate
Confidence
59%
ROE
15.0%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.21 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
19.4%
Return on capital employed
EV / EBITDA
66.0×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
108.1×
EBIT covers interest
Current Ratio
1.91×
Short-term liquidity
Asset Turnover
1.35×
Revenue per ₹ of assets
Revenue CAGR (3Y)
29.4%
3-year revenue growth
Revenue CAGR (5Y)
21.7%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹8,489
Bear case
₹1,254.65
MoS -576.6%
Base case
₹2,098.75
MoS -304.5%
Bull case
₹2,763.84
MoS -207.1%
Ratio Trends
ASTRAZEN · last 9 annual periods
ROE
15.0%
ROCE
24.5%
Operating Margin
—
Debt / Equity
0.05×
PE
81.9×
EV / EBITDA
50.6×
Historical Financials
ASTRAZEN · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹814 Cr | ₹806 Cr | ₹1003 Cr | ₹1296 Cr | ₹1713 Cr | +20.5% |
| EBITDA | — | ₹101 Cr | ₹151 Cr | ₹236 Cr | ₹198 Cr | +18.3% |
| EBIT | ₹128 Cr | ₹84.0 Cr | ₹135 Cr | ₹221 Cr | — | +14.6% |
| PAT | ₹93.3 Cr | ₹61.6 Cr | ₹99.3 Cr | ₹162 Cr | ₹116 Cr | +5.5% |
| EPS (diluted) | ₹37.32 | ₹24.64 | ₹39.72 | ₹64.60 | — | +14.7% |
| CFO | ₹105 Cr | ₹101 Cr | ₹58.3 Cr | ₹27.9 Cr | ₹65.4 Cr | -11.1% |
| CapEx | — | ₹-9.6 Cr | ₹-8.5 Cr | ₹-10.8 Cr | ₹-1.8 Cr | — |
| FCF | — | ₹91.2 Cr | ₹49.8 Cr | ₹17.1 Cr | ₹63.6 Cr | -8.6% |
| Total Assets | — | ₹857 Cr | ₹985 Cr | ₹1078 Cr | ₹1518 Cr | +15.4% |
| Total Debt | — | ₹8.6 Cr | ₹7.2 Cr | ₹4.6 Cr | ₹35.7 Cr | +42.6% |
| Shareholders' Equity | — | ₹511 Cr | ₹589 Cr | ₹712 Cr | ₹770 Cr | +10.8% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ASTRAZEN vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| PPLPHARMA PPLPHARMA | — | — | Pending | 1.1% | — |
| WOCKPHARMA WOCKPHARMA | — | — | Pending | -1.0% | — |
| GLAND Gland Pharma Limited | -12.6% | 64 | Near Fair Value | 7.6% | — |
| EMCURE EMCURE | — | — | Pending | 15.3% | — |
| JBCHEPHARM JBCHEPHARM | — | — | Pending | 19.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
7 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹82.00/sh
Last payout
2025-07-18
₹32.00
Peak payout
₹32.00
Trailing yield
0.38%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. AstraZeneca Pharma India Limited (ASTRAZEN.NS) trades at 8489.00 vs a model fair value of 2098.75, a gap of -75.3%. Piotroski F-score: 7/...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ASTRAZEN →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ASTRAZEN →
Compare
Head-to-head with peers
Compare ASTRAZEN side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ASTRAZENNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.